Trial Profile
Efficacy and safety of ombitasvir/paritaprevir/ritonavir, ledipasvir/sofosbuvir, elbasvir /grazoprevir, glecaprevir/pibrentasvir after curative treatment of HCV-Related HCC - Prospective multicenter-cooperative cohort study
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Jun 2019
Price :
$35
*
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 05 Dec 2016 New trial record